Richman Chemical Launches Technology Assessment Reports for Start-Ups within the Life Science and Specialty Chemical Markets
Reports Evaluate Commercial Feasibility of New Technologies and Recommend Optimal Commercialization Strategies
Philadelphia, PA, January 14, 2015 -- Richman Chemical Inc. (RCI) today announced the commercial launch of Technology Assessment Reports (TAR’s) to assist technology start-ups, technology transfer offices (TTOs) and other emerging life science and specialty chemical businesses. The Technology Assessment Report will advise if a new technology is commercially feasible based on "as-is" production processes, while offering cost-effective production improvement strategies and recommendations for accelerated commercialization.
“University and Non-Profit technology transfer offices represent a significant market for such reports. These entities seek to license in-house technology to outside companies and investors, yet do not have the resources or expertise to evaluate commercial feasibility. Meanwhile, potential investors and partners prefer independent analysis that a technology is commercially viable before making the decision whether to invest,” commented Christopher Kulp, Executive Vice President at Richman Chemical. He continued, “Almost all start-up firms in the chemical and life science industries face similar challenges in developing and successfully commercializing their technologies.”
Richman Chemical provides an independent analysis of the chemical process and engineering plan behind a new technology. The Technology Assessment Report serves as a critical resource for conducting needs analysis, identifying process efficiencies and deficiencies and helping project leaders properly allocate limited resources.
In its Technology Assessment Report, RCI analyzes the complete production scheme for commercial viability. For example, the choices of reagents and intermediates are evaluated for optimal performance, cost and availability. Impurities, by-products and yields are evaluated with a view towards cost savings opportunities, alternative processes and potential regulatory concerns. RCI also recommends the most cost-effective raw material sourcing options, while focusing on improving process efficiencies in order to optimize commercial scale manufacturing.
TARs typically are offered at reasonable, fixed-bid price points and can be customized to accommodate specific budget and content requests. Specific queries can be submitted on-line at http://www.richmanchemical.com/tech-assessment-funding-opportunity-inquiry/.
About Richman Chemical
Richman Chemical, Inc. provides custom chemical synthesis, custom manufacturing and raw material sourcing in the life sciences, specialty chemical, biotechnology, pharmaceutical and emerging technology industries. RCI’s Consulting Services include patent research, analysis and recommendation of process changes, identification of qualified investment resources, technology licensing guidance and more. Founded in 1988 by Ed Richman, the company is headquartered outside of Philadelphia. For more information visit www.richmanchemical.com and follow us on LinkedIn.
Richman Chemical, Inc.
215-628-2946, ext. 14